Literature DB >> 3936816

Detecting mitomycin C in human plasma during intravesical therapy.

K Jauhiainen.   

Abstract

Mitomycin C (MMC) concentrations in plasma and urine were measured in five patients with intact bladder during intravesical instillation therapy. No MMC was detected in plasma by a selective high performance liquid chromatographic (HPLC) method. The detection limit of the method is 1 ng/ml. Our results are in accordance with clinical experiences of the lack of systemic toxicity during MMC instillation therapy. There was a remarkable loss of MMC in the voided urine. The probable explanation could be that a considerable amount of MMC is absorbed into the bladder wall.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936816     DOI: 10.1007/bf02082487

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

1.  Thiotepa in the treatment of tumours of the bladder.

Authors:  H C JONES; J SWINNEY
Journal:  Lancet       Date:  1961-09-16       Impact factor: 79.321

2.  Permeability of normal and diseased human bladder epithelium.

Authors:  G J Fellows
Journal:  Proc R Soc Med       Date:  1972-03

3.  Permeability of normal and cancerous rat bladder to antineoplastic agents.

Authors:  J D Bessman; R K Johnson; A Goldin
Journal:  Urology       Date:  1975-08       Impact factor: 2.649

4.  The effect of mitomycin C on superficial bladder cancer.

Authors:  M S Soloway; W M Murphy; M D DeFuria; S Crooke; P Finebaum
Journal:  J Urol       Date:  1981-05       Impact factor: 7.450

Review 5.  Rationale for intensive intravesical chemotherapy for superficial bladder cancer.

Authors:  M S Soloway
Journal:  J Urol       Date:  1980-04       Impact factor: 7.450

6.  Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration.

Authors:  G H Jacobi; K H Kurth
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

7.  Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.

Authors:  M Pavone-Macaluso; N Gebbia; F Biondo; S Bertolini; G Caramia; F P Rizzo
Journal:  Urol Res       Date:  1976-04-21

8.  Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report.

Authors:  M D DeFuria; R B Bracken; D E Johnson; M S Soloway; C E Merrin; L R Morgan; H C Miller; S T Crooke
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

9.  Epodyl treatment of bladder tumours.

Authors:  H V Nielsen; E Thybo
Journal:  Scand J Urol Nephrol       Date:  1979

10.  Side effects associated with intravesical mitomycin.

Authors:  I Nissenkorn; H Herrod; M S Soloway
Journal:  J Urol       Date:  1981-11       Impact factor: 7.450

View more
  1 in total

Review 1.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.